RNA Targeted Therapeutics Market Growth and Forecast

RNA Targeted Therapeutics Market Growth and Forecast

The RNA Targeted Therapeutics Market is at an inflection point as delivery innovations accelerate clinical success. Industry trends in 2024–2025 highlight intensified R&D spending and diversified pipelines, expanding the industry size across oncology and genetic disorders. Comprehensive market analysis suggests that industry share gains by specialized biotech firms are reshaping competition and business growth opportunities. This blog integrates data-backed insights to illuminate forthcoming market growth strategies.

Market Size and Overview

The RNA targeted therapeutics market is estimated to be valued at USD 1.81 Bn in 2025 and is expected to reach USD 15.10 Bn by 2032, growing at a compound annual growth rate (CAGR) of 35.4% from 2025 to 2032.

This market forecast highlights increasing prioritization of lipid nanoparticle and conjugate technologies. A recent market report underscores that 2024 saw a 28% year-on-year rise in pipeline investments, driving market revenue to new heights. As these therapies progress through clinical phases, RNA Targeted Therapeutics Market share growth across oncology, genetic disorders, and metabolic disease applications is anticipated.

Market Segmentation

• Product Type: The RNA Targeted Therapeutics Market segments into antisense oligonucleotides, siRNA, miRNA therapeutics, and aptamers. Antisense oligonucleotides dominated in 2024 with USD 450 M revenue, propelled by Ionis’s inotersen. The fastest‐growing sub-segment was siRNA, which saw a 38% revenue uptick in 2025 following Alnylam’s givosiran approval. This segmentation highlights critical market trends in gene silencing modalities.
• Application: Oncology, genetic disorders, metabolic diseases, and infectious diseases define this axis. Oncology led in 2024 with over USD 600 M revenue, while genetic disorders exhibited a 42% CAGR in 2025 thanks to novel SMA-targeting therapies. These shifts reflect evolving market dynamics and opportunities in precision medicine.
• End User: Pharmaceutical and biotech companies, research institutes, and CROs form the end-user base. Pharma/biotech firms procured USD 800 M in platforms in 2024, while CROs grew fastest at 45% in 2025 due to expanded outsourcing. These insights clarify stakeholder-specific growth strategies.

Market Drivers

According to recent market research, one key market driver fueling RNA Targeted Therapeutics Market growth is escalating R&D investment in novel delivery technologies. In 2024, global funding for lipid nanoparticle and conjugate platforms surpassed USD 500 M, catalyzing a 30% increase in preclinical pipelines. Regulatory support from accelerated approval pathways—five such designations granted in 2025—has further reduced time-to-market, unlocking market opportunities. While supply chain hurdles and delivery vector scalability remain notable market restraints, recent contract manufacturing capacity expansions have mitigated several bottlenecks. The broadening market scope into metabolic and infectious diseases underscores robust business growth and highlights future market challenges.

Segment Analysis

Within product type, siRNA therapeutics emerge as the most influential segment in terms of revenue performance. SiRNA contributions soared to USD 620 M in 2025, representing a 38% jump from the previous year. A case study of Alnylam’s givosiran approval revealed a 25% reduction in hepatic porphyria biomarkers within two months, validating clinical efficacy and accelerating market adoption. Meanwhile, miRNA therapeutics, though smaller, exhibited the fastest growth at a 40% CAGR in 2025 due to novel diagnostics-driven targeting approaches. These trends in the RNA Targeted Therapeutics Market revenue underline strategic prioritization of high-potency silencing agents.

Consumer Behaviour Insights

In 2024–2025, buyer decision-making in RNA Targeted Therapeutics shifted markedly towards platform versatility and data transparency. According to a 2025 survey by BioPharma Insights, 68% of procurement leads prioritized delivery efficiency metrics over price, highlighting reduced pricing sensitivity for high-efficacy systems. Sustainability preferences rose, with 54% of research institutes seeking green chemistry processes in oligonucleotide synthesis, driving suppliers to adopt eco-friendly phosphoramidite alternatives. Digital consumption habits also evolved: 60% of pharmaceutical R&D teams subscribed to real-time analytics dashboards for patient stratification, underscoring a trend toward data-driven purchasing in specialized biotechnology segments. These shifts will influence future RNA Targeted Therapeutics Market share distributions.

Key Players

• Alnylam Pharmaceuticals
• Ionis Pharmaceuticals
• Moderna Therapeutics
• Abivax
• AC Immune
• Arrakis Therapeutics
• eFFECTOR Therapeutics
• Eloxx Pharmaceuticals
• Silence Therapeutics
• Wave Life Sciences
• Dicerna Pharmaceuticals
• Arrowhead Pharmaceuticals
• Roche
• Novartis
• Merck & Co.

Throughout 2024–2025, leading market players executed capacity expansions, product launches, and geographic entries. For instance, Alnylam Pharmaceuticals expanded its manufacturing plant in Ireland in 2024, boosting RNA Targeted Therapeutics Market revenue by 20%. Ionis Pharmaceuticals launched two next-generation antisense candidates in 2025, accelerating its clinical portfolio by 30%. Arrowhead Pharmaceuticals entered the Asia-Pacific region with a strategic partnership in 2024, diversifying market companies’ footprints and capturing regional growth.

Key winning strategies adopted by key players

Arrowhead Pharmaceuticals in 2024 pioneered a lab-to-clinic digital twin modeling approach for its liver-targeted RNA therapeutics, reducing batch failures by 25% and cutting development timelines by six months. In 2025, Silence Therapeutics launched an AI-driven sequence screening platform that shortened lead identification cycles by 40%, generating enhanced pipeline velocity. Additionally, Ionis Pharmaceuticals established a novel public–private consortium in 2025 focused on green phosphoramidite synthesis, setting an industry benchmark and addressing sustainability challenges within the RNA Targeted Therapeutics Market trends.

FAQs

1. Who are the dominant players in the RNA Targeted Therapeutics Market?
Leading players include Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Moderna Therapeutics, Abivax, AC Immune, Arrakis Therapeutics, eFFECTOR Therapeutics, and Eloxx Pharmaceuticals. Their pipelines and strategic expansions have driven significant market growth.

2. What will be the size of the RNA Targeted Therapeutics Market in the coming years?
The market is projected to grow from USD 1.81 Bn in 2025 to USD 15.10 Bn by 2032, at a CAGR of 35% during the forecast period.

3. Which end-user segment has the largest growth opportunity?
Contract research organizations (CROs) showed the fastest growth at 45% in 2025, driven by increased outsourcing of preclinical and clinical services.

4. How will market development trends evolve over the next five years?
Continued investment in delivery platforms, AI-driven discovery, and sustainability-focused chemistry will shape the next wave of RNA Targeted Therapeutics Market development trends, accelerating clinical throughput and commercialization.

5. What is the nature of the competitive landscape and challenges in the RNA Targeted Therapeutics Market?
The landscape is highly competitive, with specialized biotech and major pharma firms vying on platform efficacy, delivery innovation, and cost optimization. Key challenges include delivery vector scalability and regulatory complexities.

6. What go-to-market strategies are commonly adopted in the RNA Targeted Therapeutics Market?
Partnerships for platform access, regional manufacturing expansions, and data-driven collaborations are common. Leading companies also leverage consortiums and digital modeling to streamline development and commercialization.

‣ Get More Insights On: RNA Targeted Therapeutics Market

‣ Get this Report in Japanese Language: RNA標的治療薬市場

‣ Get this Report in Korean Language: RNA표적치료제시장

About Author:

Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)